reported figure [2] . Japan was an early adopter of hepatic arterial infusion chemotherapy (HAIC), and this treatment was performed in 4.5% of patients with advanced HCC in the 20th survey ( Fig. 1) [3, 4] . Because the molecular targeted agent, sorafenib, was approved in Japan in 2009, the proportion of patients who underwent systemic therapy was still low (0.9%). In addition, the proportion of patients who received only best supportive care as the initial treatment was 0.9%, indicating that some form of therapy was offered to many patients in Japan after their initial diagnosis [5] . This was also true for Child-Pugh grade C and Barcelona Clinic Liver Cancer (BCLC) stage D; the proportion of patients who received best supportive care as the initial treatment after initial detection of HCC was extremely low (0.9%) [5, 6] . Portal vein tumor thrombosis was revealed to be a factor strongly associated with poor prognosis. When the overall survival (OS) rates of HCC patients who had undergone resection were compared by severity of portal vein invasion, median OS was found to decrease according to the extent of invasion: 97 months in patients with no portal vein invasion (Vp0), 61 months in those with Vp1, 26 months in those with Vp2, and 16 months in those with Vp3-Vp4 (Fig. 2 ). In addition, AFP level is also a strong predictor of prognosis and can serve as a prognosticator. When the OS of 28,017 HCC patients who had undergone hepatectomy was compared by serum AFP level, median OS decreased as AFP level increased: 114 months in patients with an AFP level ≤20 ng/mL, and 27 months in those with an AFP level > 10,000 ng/mL (Fig. 3) . These results clearly show that portal vein invasion and AFP level are extremely important predictors of prognosis as well as prognostic factors in patients with HCC.
Comparison of median OS across four 8-year periods (registration period I, 1978 -1985 period II, 1986 period II, -1993 period III, 1994 period III, -2001 and period IV, 2002-2009) shows clear improvement in median OS over the years: 5 months in period I, 25.6 months in period II, 43.0 months in period III, and 60.8 months in period IV (Fig. 4) . Five-year survival rate also steadily improved: 11.9% in period I, 25.5% in period II, 39.7% in period III, and 50.4% in period IV. These data show a marked improvement in HCC prognosis compared with the results of the previous survey [2] . The above survival results were of patients in Japan with HCC at any stage (from BCLC stage 0 to stage D). It is clear that the complete establishment of a nationwide surveillance program increased the number of patients whose HCC was detected at an early stage; consequently, more HCC patients were able to receive curative therapy. This means that more patients benefited from curative treatment, which resulted in prolonged survival. ≤20 (n = 14,319) >20 to ≥200 (n = 7,044) >200 to ≥400 (n = 1,425) >400 to ≥1,000 (n = 1,647) 
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